Free Republic

Cancer blood-test maker Grail said about 400 customers were mistakenly notified that its test detected a cancer signal in them, which the company attributed to a partner’s software glitch. Grail said its laboratory test didn’t turn up the incorrect results, but rather the letters sent out to the customers were wrong. Because of the software problem, more than half of the customers were told they may have cancer even before they had taken the test, Grail said. Grail, a Menlo Park, Calif., unit of gene-sequencing company Illumina, is the leading developer of multi-cancer early-detection blood tests, an emerging market that...

The final results from a Grail study of its cancer-tracing blood test found it was accurate at detecting a range of different tumors at early stages—especially those more likely to be lethal and have fewer screening options. Grail launched its prescription Galleri diagnostic in the U.S. earlier this month. The test is designed to help spot as many as 50 different cancers and uncover their original organ sites from a blood sample… In a paper published in… cancer journal Annals of Oncology using data gathered from the company’s Circulating Cell-free Genome Atlas study, researchers found the test could detect cancer...